Methods of detecting septic arthritis, transient synovitis and osteomyelitis
AssigneeWashington University
InventorScott Luhmann
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for detecting septic arthritis, transient synovitis, or osteomyelitis, based on protein signatures. Specifically, the method comprising: (i) measuring expression levels of one or more proteins in a biological sample obtained from the subject; (ii) determining a protein signature correlated with a detected disease based on the expression levels of the proteins in step (i); and (iii) assessing the occurrence or severity of the subject correlated with the disease based on the protein signature determined in step (ii). The methods may further comprise identifying suitable treatment for the patient based on the protein signatures.
Claims22
A method of identifying a subject having septic arthritis, the method comprising:
- (i) measuring expression levels of one or more proteins selected from the group consisting of TGFα, IL-7, IL-33 and IL-28A in a biological sample obtained from the subject;
- (ii) determining a septic arthritis protein signature based on the expression levels of the proteins in step (i);
- and
- (iii) assessing septic arthritis occurrence or severity of the subject based on the protein signature determined in step (ii).
A method of identifying a subject having transient synovitis, the method comprising:
- (i) measuring expression levels of one or more proteins selected from the group consisting of TGFα, IL-7, IL-33 and IL-28A in a biological sample obtained from the subject;
- (ii) determining a transient synovitis protein signature based on the expression levels of the proteins in step (i);
- and
- (iii) assessing transient synovitis occurrence or severity of the subject based on the protein signature determined in step (ii).
(canceled)
A method of identifying a subject having osteomyelitis, the method comprising:
- (i) measuring expression levels of one or more of procalcitonin, Type II collagen degradation (CTX-II), Type IIA Collagen N-Propeptide (PIIANP), and C1-2C Bone and Cartilage Degradation (C1-2C) in a biological sample obtained from the subject;
- (ii) determining a osteomyelitis protein signature based on the expression levels of the proteins in step (i);
- and
- (iii) assessing osteomyelitis occurrence or severity of the subject based on the protein signature determined in step (ii).
(canceled)
Dependencies are inferred from the claim text.